My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.050 -0.210 (-2.54%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 12, 2025

Via Benzinga

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗

May 24, 2025

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Via Benzinga

Topics Government

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗

May 20, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Uncovering Potential: Compass Pathways's Earnings Preview ↗

October 30, 2024

Via Benzinga

Why Compass Pathways Stock Was a Double-Digit Winner This Week ↗

April 25, 2025

Via The Motley Fool

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish ↗

March 06, 2025

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Via Stocktwits

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says ↗

February 27, 2025

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Via Benzinga

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript ↗

February 27, 2025

CMPS earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday ↗

February 27, 2025

Via Benzinga

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months ↗

February 14, 2025

Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.

Via Stocktwits

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗

February 12, 2025

The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Via Investor's Business Daily

Is Your Mind Ready to Consider Investing in Psychedelics Stocks? ↗

November 29, 2024

Don't jump in without doing some research first.

Via The Motley Fool

COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co? ↗

November 25, 2024

COMPASS Pathways faces $43M market cap loss, raising concerns among institutional investors holding 30% ownership.

Via Benzinga

Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗

November 15, 2024

Via Benzinga

Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗

November 15, 2024

President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

Via Investor's Business Daily

Topics Government

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment ↗

November 14, 2024

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.

Via Benzinga

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? ↗

November 13, 2024

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.

Via Benzinga

Topics Artificial Intelligence

Top 3 Health Care Stocks You'll Regret Missing In November ↗

November 05, 2024

Via Benzinga

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript ↗

October 31, 2024

CMPS earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results ↗

October 31, 2024

Via Benzinga

As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash ↗

October 31, 2024

Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 31, 2024

Via Benzinga

Crude Oil Gains 1%; Meta Shares Fall Following Q3 Results ↗

October 31, 2024

Via Benzinga

Estée Lauder, Robinhood, eBay And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 25, 2024

Via Benzinga

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗

October 07, 2024

Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.